使用新型示踪剂[64Cu]Cu-DOTA-PSMA-3Q在前列腺癌靶向活检中实时诊断取样病灶:一项先导性临床前研究
本研究合成新型PSMA示踪剂[64Cu]Cu-DOTA-PSMA-3Q,在临床前验证其PSMA特异性和安全性,并前瞻性纳入18例疑似前列腺癌患者行PET/CT显像,其中10例在注射后24小时行靶向穿刺联合标准模板穿刺,术中采用伽马能谱仪定量活检组织放射性计数。结果显示前列腺癌组织计数显著高于正常组织,ROC曲线AUC为0.8837,最佳诊断 cutoff 为66 CPM,灵敏度77.36%。
要点
- 注射后2小时PET/CT可显示前列腺内外全部PSMA阳性病灶。
- 10例患者共获取132条穿刺芯,其中53条组织学确诊为前列腺癌。
- 前列腺癌组织计数中位数134,148 CPM显著高于正常前列腺组织18,39 CPM(P < 0.001)。
核心结论
- 使用[64Cu]Cu-DOTA-PSMA-3Q的辐射引导技术提高了PSMA-PET图像引导活检的可靠性,可在手术过程中即时确认取样病灶,并具有实现优化穿刺结果的潜力。
研究设计与样本
- 先导性临床前研究:合成[64Cu]Cu-DOTA-PSMA-3Q并验证其PSMA特异性和安全性;前瞻性纳入18例疑似前列腺癌患者行PET/CT显像,其中10例在注射后24小时间隔行靶向穿刺联合标准模板穿刺,术中采用伽马能谱仪以每分钟计数(CPM)定量活检组织放射性。
- 试验注册:中国临床试验注册中心ChiCTR2300072655,注册日期2023年6月20日。
主要发现
- 临床前细胞和动物研究证实[64Cu]Cu-DOTA-PSMA-3Q的效能和特异性。
- 临床中注射后2小时PET/CT显像可显示前列腺内外全部PSMA阳性病灶。
- 人体器官辐射暴露评估显示肾脏吸收剂量最高,其次为膀胱壁、唾液腺和肝脏。
- 10例患者共取出132条穿刺芯,其中53条组织学确诊为前列腺癌。
- 前列腺癌组织CPM中位数为134,148,正常前列腺组织为18,39 CPM,前者显著高于后者(P < 0.001)。
关键数值与推荐
- 最佳诊断截断值为66 CPM,灵敏度77.36%。
- 前列腺癌组织CPM中位数134,148 vs 正常前列腺组织18,39 CPM(P < 0.001)。
- ROC曲线AUC为0.8837。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Prostate-specific membrane antigen positron emission tomography (PSMA-PET) guided targeted biopsy has shown potential for detecting more prostate cancer (PCa) cases. However, relying exclusively on imaging may risk missing lesions, an issue that could be addressed by incorporating radiation-guided technology. Accordingly, we aimed to develop a novel PSMA radiotracer with a long half-life, [64Cu]Cu-DOTA-PSMA-3Q, and evaluate its targeting accuracy. Additionally, this research explored the practicability of real-time lesion verification during surgical interventions. METHODS: In this study, we synthesized the radiotracer [64Cu]Cu-DOTA-PSMA-3Q and verified its PSMA specificity and safety. We prospectively enrolled 18 patients with suspected PCa for PET/CT imaging to assess the efficacy of PCa detection; 10 patients underwent targeted biopsy combined with standard template biopsy at an interval of 24 h after injection. The radioactivity of the biopsy tissue was quantified in counts per minute (CPM) using a gamma spectrometer intraoperatively. RESULTS: The efficacy and specificity of [64Cu]Cu-DOTA-PSMA-3Q were confirmed through preclinical cell and animal studies. In clinical settings, PET/CT imaging performed 2 h after injection visualized all of the PSMA-positive lesions both within and outside the prostate. The assessment of human organ radiation exposure indicated that the kidneys received the highest absorbed dose, followed by the bladder wall, salivary glands, and liver. In 10 patients, a total of 132 biopsy cores were extracted, with 53 cores histologically confirmed as PCa. The median CPM for PCa tissues was significantly greater at 134,148 CPM compared to 18,39 CPM for normal prostate tissues (P < 0.001). Receiver operating characteristic (ROC) curve analysis yielded an AUC of 0.8837, suggesting high diagnostic accuracy. The optimal diagnostic cut-off was established at 66 CPM, achieving a sensitivity of 77.36%. CONCLUSIONS: Radiation-guided technology using [64Cu]Cu-DOTA-PSMA-3Q improves the reliability of PSMA-PET image-guided biopsy, enables instant confirmation of sample lesions during surgical procedures, and holds potential for achieving optimized puncture outcomes. TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR2300072655, Registered 20 June 2023.
引用
- Zhang J, Niu S, Liu Y, et al. Real-time diagnosis of sampled lesions in targeted biopsy of prostate Cancer using a novel tracer [64Cu] Cu-DOTA-PSMA-3Q: a pilot preclinical study. Eur J Nucl Med Mol Imaging. 2024. PMID: 39614910. doi:10.1007/s00259-024-07000-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。